Extended indication Extension of indication to include treatment of iron deficiency anaemia in paediatric population (adolescents aged 12 years and above).
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Active substance Ferrimaltol
Domain Cardiovascular diseases
Reason of inclusion Indication extension IND
Main indication Other non-oncological hematological medications
Extended indication Extension of indication to include treatment of iron deficiency anaemia in paediatric population (adolescents aged 12 years and above).
Proprietary name Feraccru
Manufacturer Norgine
Mechanism of action Unknown
Route of administration Oral
Therapeutical formulation Oral suspension
Budgetting framework Extramural (GVS)

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
Particularity Unknown
ATMP No
Submission date June 2025
Expected Registration April 2026
Orphan drug No
Registration phase Registration application pending

Therapeutic value

Current treatment options Orale ferripreparaten
Therapeutic value No estimate possible yet

This assessment does not indicate any potential inclusion in the package.

References NCT05126901 (FORTIS); Schmidt et al. J Clin Med. 2021; Expertopinie

Expected patient volume per year

Patient volume < 10

Market share is generally not included unless otherwise stated.

References Declaratiedata
Additional remarks In 2024 waren er 27 gebruikers van orale ferripreparaten in Nederland. Met deze indicatieuitbreiding zal dit getal iets toenemen.

Expected cost per patient per year

Potential total cost per year

Off label use

Off label use Unknown

Indication extension

Indication extensions Unknown

Other information